title: Metabolism of tirapazamine by multiple reductases in the nucleus.
abstract: Tirapazamine (TPZ, 3-amino-1,2,4-benzotriazine 1,4-di-N-oxide, SR4233, Tirazone), a bioreductive drug currently in clinical trials, is selectively toxic to hypoxic cells commonly found in solid tumors. The toxicity results from the intracellular metabolism of TPZ to a highly toxic radical. When oxygen levels are low, the TPZ radical reacts with cellular molecules, producing DNA damage and cell death. The much lower toxicity towards aerobic cells results from the back-oxidation of the TPZ radical by oxygen. A major unresolved aspect of the mechanism of TPZ is the identity of the reductase(s) in the cell responsible for activating the drug to its toxic form. We have studied both the metabolism of the drug using HPLC and the formation of the TPZ radical with a fluorescence assay using dihydrorhodamine 123. We also measured DNA double- and single-strand breaks produced by TPZ, using the comet assay. We demonstrated that multiple reductases in the nucleus metabolize TPZ under hypoxia. Using the cofactor dependence of the reductases for metabolizing TPZ and of the DNA damage caused by TPZ, we show that DNA single-strand breaks after TPZ metabolism are probably caused by the most abundant source of reductase in the nucleus. DNA double-strand breaks, on the other hand, are formed by TPZ metabolism by an unknown nuclear reductase that requires only NADPH for its activity. This study is the first to characterize multiple nuclear reductases capable of activating TPZ.
authors.affiliation: Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University Medical School, Stanford, CA 94305-5152, USA.
authors.forename: Y M
authors.initials: YM
authors.lastname: Delahoussaye
authors.forename: J W
authors.initials: JW
authors.lastname: Evans
authors.forename: J M
authors.initials: JM
authors.lastname: Brown
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism* / Q000633:toxicity; D002467:Cell Nucleus / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D020552:Comet Assay; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D004249:DNA Damage; D005609:Free Radicals / Q000032:analysis; D006367:HeLa Cells; D006801:Humans; D007700:Kinetics; D009243:NAD / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D009687:Nuclear Proteins / Q000302:isolation & purification; D010088:Oxidoreductases / Q000378:metabolism*; D000077704:Tirapazamine; D014227:Triazines / Q000378:metabolism* / Q000633:toxicity
chemical_list: D000970:Antineoplastic Agents; D005609:Free Radicals; D009687:Nuclear Proteins; D014227:Triazines; D009243:NAD; D000077704:Tirapazamine; D009249:NADP; D004247:DNA; D010088:Oxidoreductases; D009251:NADPH-Ferrihemoprotein Reductase